TREM1 and neoplasm: By employing both CRISPR-Cas9-mediated KO and the small molecule inhibitor VJDT, we demonstrated that TREM1 inhibition significantly reduces tumor size, depletes the number of LCSLCs, and impairs spheroid formation.